A High throughput Reverse Genetics System for Hepatitis C Virus
丙型肝炎病毒的高通量反向遗传学系统
基本信息
- 批准号:8891839
- 负责人:
- 金额:$ 7.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-04-10 至 2017-03-31
- 项目状态:已结题
- 来源:
- 关键词:3&apos Untranslated RegionsAntiviral AgentsAntiviral TherapyCell Culture SystemCell Culture TechniquesCellsCharacteristicsChronic Hepatitis CClinicalConsensus SequenceDrug resistanceFrustrationGenerationsGeneticGenetic VariationGenomeGenomicsGenotypeGoalsHepatitis CHepatitis C virusIn VitroLegal patentLengthLife Cycle StagesLiver diseasesMeasurementMethodsModelingMutationNamesNaturePatientsPhenotypePlasmidsPopulationPreparationPreventivePrimary carcinoma of the liver cellsProcessPublic HealthRNA Polymerase IRNA VirusesResearchReverse Transcriptase Polymerase Chain ReactionSystemTechniquesTestingTransfectionUnited StatesUntranslated RegionsVaccinesViralViral GenomeVirusWorkbasecombatgenetic approachin vitro Modelin vivoliver transplantationparticlepublic health relevancereverse geneticsscreeningtool
项目摘要
DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) is one of medically important RNA viruses and causes a wide spectrum of liver diseases, which are also a leading indication for liver transplantation in the United States. Given its high priority in public health, an in vito model for HCV life cycle is highly demanded for both basic and translational HCV research, however, current in vitro HCV models could only mimic some steps of viral life cycle. There is so far only one particular HCV genotype 2a strain, named JFH1, is able to be propagated in vitro. The JFH1-based cell culture has been established through the rescue of infectious viruses from cloned viral genomes, so called reverse genetics approach. A well-known constraint in such an approach is the unpredictability of viral mutations introduced internally or externally during the preparation of full-length viral clones. Some of these mutations may be lethal or detrimental for successful rescue of infectious viruses, in particular in the setting of HCV due to its coordinated
genome network and remarkable genetic diversity. When the number of strains/clones tested is large enough to overcome the barrier of mutations from either heterogeneous viral population or experimental introduction, HCV cell culture could be established with strains other than JFH1. However, this goal is hard to be achieved by conventional reverse genetics that is notable for its tedious process. Based on our previous work, we thus propose to develop a rapid reverse genetics platform capable of screening clinical HCV isolates in a high-throughput manner. We hypothesize that the establishment of such a platform is feasible by the integration of our long RT-PCR technique (US patent No: 7,786,294 B2) and a seamless assembly method. The proposed platform is a plasmid-based reverse genetics in which long RT-PCR and 3'UTR amplicons of HCV will be fused into the target plasmid using the Gibson assembly method, followed by direct transfection into Huh-7 cells and subsequent measurement of potential infectious viruses. We will screen a total of 61 patient-derived HCV 1a strains that have already been characterized for viral mutations at the full-length genome level. The method developed with the proposed project has general applicability in RNA viruses other than HCV.
描述(申请人提供):丙型肝炎病毒(丙型肝炎病毒)是一种重要的医学核糖核酸病毒,可引起多种肝脏疾病,也是美国肝移植的主要适应症。鉴于其在公共卫生中的高度重要性,无论是基础研究还是翻译研究都迫切需要建立一个描述丙型肝炎病毒生命周期的体外模型,然而,目前的体外模型只能模拟病毒生命周期的某些步骤。到目前为止,只有一种特殊的丙型肝炎病毒2a株,命名为JFH1,能够在体外繁殖。基于JFH1的细胞培养是通过从克隆的病毒基因组中拯救传染性病毒而建立的,即所谓的反向遗传学方法。这种方法的一个众所周知的限制是在准备全长病毒克隆期间内部或外部引入的病毒突变的不可预测性。这些突变中的一些可能对成功抢救感染性病毒是致命的或有害的,特别是在丙型肝炎病毒的背景下,由于其协调
基因组网络和显著的遗传多样性。当被测试的菌株/克隆的数量足够大,足以克服来自异质病毒群体或实验引入的突变的障碍时,可以用JFH1以外的菌株建立丙型肝炎病毒细胞培养。然而,以繁琐的过程著称的传统反向遗传学很难实现这一目标。因此,在前期工作的基础上,我们建议建立一个能够高通量筛选临床分离的丙型肝炎病毒的快速反向遗传学平台。我们假设,通过整合我们的长RT-PCR技术(美国专利号:7,786,294 B2)和无缝组装方法,建立这样一个平台是可行的。该平台是一种以质粒为基础的反向遗传学方法,利用Gibson组装方法将长的RT-PCR和丙型肝炎病毒的3‘非编码区扩增片段融合到目标质粒中,然后直接转染Huh-7细胞,随后检测潜在的感染性病毒。我们将筛选总共61个患者来源的丙型肝炎病毒1a毒株,这些毒株已经在全基因组水平上被表征为病毒突变。该方法对丙型肝炎病毒以外的RNA病毒具有普遍的适用性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
XIAOFENG FAN其他文献
XIAOFENG FAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('XIAOFENG FAN', 18)}}的其他基金
Transcriptomic Quantitation of Hepatitis B Virus Surface Antigen from Integration
通过整合对乙型肝炎病毒表面抗原进行转录组定量
- 批准号:
10724716 - 财政年份:2023
- 资助金额:
$ 7.58万 - 项目类别:
A Novel Human Virus in Patients with Cryptogenic Liver Disease
隐源性肝病患者中的一种新型人类病毒
- 批准号:
10636331 - 财政年份:2023
- 资助金额:
$ 7.58万 - 项目类别:
Hepatitis C Virus Quasispecies in the Resistance to Antiviral Therapy
丙型肝炎病毒准种对抗病毒治疗的耐药性
- 批准号:
7570083 - 财政年份:2008
- 资助金额:
$ 7.58万 - 项目类别:
Hepatitis C Virus Quasispecies in the Resistance to Antiviral Therapy
丙型肝炎病毒准种对抗病毒治疗的耐药性
- 批准号:
8037137 - 财政年份:2008
- 资助金额:
$ 7.58万 - 项目类别:
Hepatitis C Virus Quasispecies in the Resistance to Antiviral Therapy
丙型肝炎病毒准种对抗病毒治疗的耐药性
- 批准号:
8242874 - 财政年份:2008
- 资助金额:
$ 7.58万 - 项目类别:
Hepatitis C Virus Quasispecies in the Resistance to Antiviral Therapy
丙型肝炎病毒准种对抗病毒治疗的耐药性
- 批准号:
7774317 - 财政年份:2008
- 资助金额:
$ 7.58万 - 项目类别:
相似海外基金
Impact of alternative polyadenylation of 3'-untranslated regions in the PI3K/AKT cascade on microRNA
PI3K/AKT 级联中 3-非翻译区的替代多聚腺苷酸化对 microRNA 的影响
- 批准号:
573541-2022 - 财政年份:2022
- 资助金额:
$ 7.58万 - 项目类别:
University Undergraduate Student Research Awards
How do untranslated regions of cannabinoid receptor type 1 mRNA determine receptor subcellular localisation and function?
1 型大麻素受体 mRNA 的非翻译区如何决定受体亚细胞定位和功能?
- 批准号:
2744317 - 财政年份:2022
- 资助金额:
$ 7.58万 - 项目类别:
Studentship
MICA:Synthetic untranslated regions for direct delivery of therapeutic mRNAs
MICA:用于直接递送治疗性 mRNA 的合成非翻译区
- 批准号:
MR/V010948/1 - 财政年份:2021
- 资助金额:
$ 7.58万 - 项目类别:
Research Grant
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10019570 - 财政年份:2019
- 资助金额:
$ 7.58万 - 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10223370 - 财政年份:2019
- 资助金额:
$ 7.58万 - 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10455108 - 财政年份:2019
- 资助金额:
$ 7.58万 - 项目类别:
Synergistic microRNA-binding sites, and 3' untranslated regions: a dialogue of silence
协同的 microRNA 结合位点和 3 非翻译区:沉默的对话
- 批准号:
255762 - 财政年份:2012
- 资助金额:
$ 7.58万 - 项目类别:
Operating Grants
Analysis of long untranslated regions in Nipah virus genome
尼帕病毒基因组长非翻译区分析
- 批准号:
20790351 - 财政年份:2008
- 资助金额:
$ 7.58万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Search for mRNA elements involved in the compatibility between 5' untranslated regions and coding regions in chloroplast translation
寻找参与叶绿体翻译中 5 非翻译区和编码区之间兼容性的 mRNA 元件
- 批准号:
19370021 - 财政年份:2007
- 资助金额:
$ 7.58万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Post-transcriptional Regulation of PPAR-g Expression by 5'-Untranslated Regions
5-非翻译区对 PPAR-g 表达的转录后调控
- 批准号:
7131841 - 财政年份:2006
- 资助金额:
$ 7.58万 - 项目类别:














{{item.name}}会员




